Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compounds.
McCormack
J J
JJ
Laboratory of Medicinal Chemistry and Biology, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20205, USA.
Marquez
V E
VE
Liu
P S
PS
Vistica
D T
DT
Driscoll
J S
JS
D000818:Animals; D000963:Antimetabolites / Q000494:pharmacology*; D002384:Catalysis; D003564:Cytidine Deaminase / Q000037:antagonists & inhibitors* / Q000302:isolation & purification; D003641:Deamination; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007668:Kidney / Q000201:enzymology; D007700:Kinetics; D008099:Liver / Q000201:enzymology; D015394:Molecular Structure; D010084:Oxidation-Reduction; D011485:Protein Binding; D011741:Pyrimidine Nucleosides / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D013056:Spectrophotometry, Ultraviolet; D013329:Structure-Activity Relationship; D013767:Tetrahydrouridine / Q000494:pharmacology*
D000963:Antimetabolites; D004791:Enzyme Inhibitors; D011741:Pyrimidine Nucleosides; D013767:Tetrahydrouridine; D003564:Cytidine Deaminase